Adaptive Cannabinoid Formulations for Niche Environments

Publication ID: 24-11857530_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Cannabinoid Formulations for Niche Environments,” Published Technical Disclosure No. 24-11857530_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857530_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,530.

Summary of the Inventive Concept

This inventive concept adapts cannabinoid formulations to specific, narrow market or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions, ensuring personalized relief and optimal efficacy.

Background and Problem Solved

The original patent disclosed cannabinoid formulations tailored to an individual's genotype. However, these formulations may not be effective in unique operational environments. This inventive concept addresses the need for cannabinoid formulations adapted to specific niche environments, ensuring optimal relief and efficacy in these contexts.

Detailed Description of the Inventive Concept

The inventive concept encompasses four primary embodiments: (1) a system for providing personalized cannabinoid formulations in high-security environments, utilizing a database of individual genotypes and a formulation generator; (2) a method for disaster relief, administering a genotype-based cannabinoid formulation to provide relief from stress and anxiety; (3) a portable cannabinoid formulation kit for extreme weather conditions, featuring a waterproof container, genotype-based selection guide, and specific CBD:THC ratios; and (4) a system for providing cannabinoid formulations in areas with limited access to medical care, leveraging remote genotype analysis and formulation generation.

Novelty and Inventive Step

The new claims introduce a novel combination of genotype-based cannabinoid formulations with specific, niche environments, providing a non-obvious solution to the limitations of the original patent. The inventive concept's adaptive approach ensures optimal efficacy and relief in unique operational environments.

Alternative Embodiments and Variations

Alternative embodiments may include formulations adapted for high-altitude environments, specialized formulations for specific medical conditions, or formulations integrated with wearable devices for real-time monitoring and adjustment. Variations may also include different ratios of CBD to THC, incorporation of additional cannabinoids or terpenes, or alternative delivery methods.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in various industries, including disaster relief, high-security environments, and extreme weather condition response. The market for adaptive cannabinoid formulations is vast, with potential applications in medical care, wellness, and recreational use.

Field of Art

Pharmaceutical formulations, specifically cannabinoid composition design with a focus on personalized medicine and targeted delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, pharmacology, or biochemistry, possessing expertise in cannabinoid research, formulation techniques, and personalized medicine approaches

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about genotype-specific cannabinoid formulations. The disclosed niche environment adaptations leverage known personalization techniques and represent logical combinations of existing cannabinoid composition principles. The systematic approach to generating context-specific formulations follows directly from the source patent's foundational genotype-based design methodology.

Obvious Combinations & Variations

Source Patent Element
Cannabinoid formulation with specific CBD:THC ratios and terpene compositions
PTD Variation
Adapting cannabinoid formulations for high-security, disaster relief, and extreme environment contexts
Obviousness Reasoning
A PHOSITA would recognize that environmental context is a predictable variable for modifying pharmaceutical compositions, representing a standard design optimization approach
Source Patent Element
Genotype-based formulation generation methodology
PTD Variation
Remote genotype analysis systems for generating customized cannabinoid formulations in limited medical access environments
Obviousness Reasoning
Extending genotype analysis to remote contexts represents a known technique for expanding personalized medicine approaches, utilizing standard telemedicine and data analysis technologies
Source Patent Element
Inclusion of multiple cannabinoids and terpenes in formulation
PTD Variation
Portable formulation kits with multiple cannabinoid ratios and genotype-based selection guides
Obviousness Reasoning
Creating modular formulation systems with selection guidance is a predictable design choice for implementing personalized medicine principles
Source Patent Element
Cannabinoid composition with specific chemical ratios and supplementary compounds
PTD Variation
Specialized formulations for stress relief, high-altitude environments, and specific medical conditions
Obviousness Reasoning
Tailoring cannabinoid compositions to specific physiological states represents a standard pharmaceutical optimization technique with predictable scientific approaches
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857530, a person having ordinary skill in the art would find the disclosed cannabinoid formulation variations obvious and anticipated, as the PTD represents a predictable extension of existing personalized medicine techniques applied to cannabinoid composition design, thereby rendering potential derivative claims obvious and non-patentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,530
TitleCannabinoid formulations
Assignee(s)Endocanna Health, Inc.